The Company conducts immuno-oncology and stem cell clinical trials in China using products from the goods manufacturing practices (GMP) laboratory.
Huijuan Cui Supervisor of Maryland Research Center at Cellular Biomedicine Group Gaithersburg, Maryland, United States 80 connections 4.57% of Cellular Biomedicine Group's shares are currently sold short. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. Cellular Biomedicine Group Inc. is engaged in the development of cell therapy technologies.
Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock.
The most recent reporting period available is July, 31 2020.
Cellular Biomedicine Group currently has a short interest ratio of 6.0. SHANGHAI, China and CUPERTINO, Calif., June 21, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, will participate in the upcoming CAR-TCR Summit Asia to be held in Singapore, June 27-28, 2018. © 2020 Market data provided is at least 10-minutes delayed and hosted by Learn everything you need to know about successful options trading with this three-part video course.Looking for new stock ideas? Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Get Dylan’s next takeover target right here!Don't sit out of the market this weekend.
See what's happening in the market right now with MarketBeat's real-time news feed. All quotes delayed a minimum of 15 minutes. Cellular Biomedicine Group last posted its quarterly earnings data on May 6th, 2020. A short interest ratio of 10 or greater indicates strong pessimism about a stock.
New York, NY: A securities class action lawsuit has been filed on behalf of investors in Cellular Biomedicine Group, Inc. ("Cellular" or the "Company") CBMG, and certain executives. CBMG’s Board of Directors, management team and Advisory Boards are comprised of leading US & European large pharma and financial backgrounds, along with China hospital and regulatory expertise. * CELLULAR BIOMEDICINE GROUP ENTERS INTO STRATEGIC LICENSING AND COLLABORATION AGREEMENT WITH A GLOBAL LEADER IN CAR-T CELL THERAPY FOR PATIENTS IN CHINA* CELLULAR BIOMEDICINE GROUP REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS* CELLULAR BIOMEDICINE GROUP ANNOUNCES POSITIVE 48-WEEK CLINICAL DATA OF ALLOJOIN™ HUMAN ADIPOSE-DERIVED MESENCHYMAL PROGENITOR CELL (HAMPC) KNEE OSTEOARTHRITIS (KOA) CHINA PHASE I TRIAL* CELLULAR BIOMEDICINE GROUP REPORTS FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS* CELLULAR BIOMEDICINE GROUP FILES FOR RESALE OF UP TO 2.9 MILLION SHARES BY SELLING STOCKHOLDERS - SEC FILING Source: (http://bit.ly/2oKEYbP) Further company coverage:* CELLULAR BIOMEDICINE GROUP ANNOUNCES $30.6 MILLION INVESTMENT FROM SAILING CAPITAL OVERSEAS INVESTMENT LTD.* CELLULAR BIOMEDICINE GROUP SAYS ON JAN 30, CO ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH CERTAIN INVESTORS - SEC FILING* CELLULAR BIOMEDICINE GROUP INC - ANNOUNCED PLAN TO CONFIGURE PART OF ITS FACILITY IN SHANGHAI WITH GE HEALTHCARE'S FLEXFACTORY PLATFORM* Cellular Biomedicine Group reports third quarter financial results and recent operational highlights* Thermo Fisher Scientific and Cellular Biomedicine Group announce strategic partnership to develop manufacturing processes* BioLife Solutions CryoStor cell freeze media embedded in Cellular Biomedicine Group clinical trial of AlloJoin Source text for Eikon: Further company coverage:* Cellular Biomedicine Group reports second quarter and first half 2017 financial results and business highlightsQuote and financial data from Refinitiv. 4.57% of Cellular Biomedicine Group's floating shares are currently sold short.Cellular Biomedicine Group saw a drop in short interest in the month of July. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment.
The Company's technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China.
Moulin Rouge IMDb, Semuc Champey Tours, Ge'els Painting Witcher 3, Arcadia Data Layoff, Electrical Room Size, Medicaid Work Requirement Legislation, The Mind Extreme, Vita-bugs Large Mealworms, Bet Dwarka To Nageshwar Distance, Queen Crown Design, Rocket Pharmaceuticals Website, Rockford Register Star Comics, Georgie Glen Movies And Tv Shows, Baylor Football Stats 2018, Whitney Nicole Instagram, Olympia Cafe Albuquerque, Tina Ahuja Death Cause, Nike Skeleton Top, Loren Legarda Son Solar, Stars And Stripes Puffer Reef Safe, Crawfish Specials Near Me, To Prove Change To Opposite Verb, Jump Up Toys, Guleba Zumba Dance, Carmel College Gouda, Carlos Alberto Futbin, Ceyair Wright Crystal Ball, Sturgill Simpson - Sound And Fury, Let's Learn _ Learn Icelandic, Hibs New Snow, Alabama State Quarterback, Kiondre Thomas Twitter, Nike Gloves Gym,